Cost effectiveness of intermittent screening followed by treatment versus intermittent preventive treatment during pregnancy in West Africa: analysis and modelling of results from a non-inferiority trial

Table 3 Cost consequence analysis

		IPTp-SP	ISTp-AL
Costs per 1000 pregnant women	Health provider excluding consequences^b (US$ 2012)	1631.84 (1100.11–2316.97)	5778.77 (4701.65–7039.15)^a
Costs per 1000 pregnant women	Health provider including consequences^b (US$ 2012)	9006.54 (5610.30–13,680.56)	13,972.79 (10,199.65–18,983.86)^a
Measurable outcomes contributing to DALYs per 1000 women [20]	LBW	151 (137–167)	156 (141–172)
	severe/moderate anaemia	17 (12–25)	23 (17–32)
	clinical malaria (total episodes)^c	74 (61–92)	115 (96–144)
Other measurable outcomes per 1000 women and side effects [20, 37]	Placental malaria: active infection (acute and chronic)	245 (224–265)	242 (222–262)
	Dizziness	46 (38–54)	25 (19–31)
	Sleeplessness	13 (9–17)	7 (4–10)
	Weakness	30 (24–37)	18 (13–23)
	Nausea	22 (16–28)	13 (9–17)
	Vomiting	45 (37–53)	26 (20–32)
Non measurable outcomes	Intrinsic value of giving less drugs to pregnant women
	Value to individual of knowing about positive test
	Value of knowing about positive test for surveillance
	Deprivation of treatment for false negatives

DALY disability adjusted life years; IPTp-SP intermittent preventive treatment with sulfadoxine-pyrimethamine; ISTp-AL intermittent screening followed by treatment with artemether-lumefantrine; LBW low birth weight
^aAt 24.7 % of administration where RDT showed a positive result
^bCosts from consequences = ∑ short term costs LBW baby; costs mod/sev anaemia episode; costs MiP episode
^cClinical malaria defined as illness + positive slide at an unscheduled visit